HSD87 Chimeric Antigen Receptor T Cell (CAR T) Therapy As Second-Line (2L) Treatment for Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Therapy Choice and Treatment Barriers Among US Oncologists
Abstract
Authors
Sarah Lucht Kristin Zimmerman Savill William John Brooke Dulka Luke Jennings-Zhang Yolaine Jeune-Smith Bruce Feinberg